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Abstract
Background: 18F-N-[3-bromo-4-(3-fluoro-propoxy)-benzyl]-guanidine (18F-LMI1195) is a new class of PET tracer
designed for sympathetic nervous imaging of the heart. The favorable image quality with high and specific neural
uptake has been previously demonstrated in animals and humans, but intracellular behavior is not yet fully
understood. The aim of the present study is to verify whether it is taken up in storage vesicles and released in
company with vesicle turnover.
Results: Both vesicle-rich (PC12) and vesicle-poor (SK-N-SH) norepinephrine-expressing cell lines were used for in
vitro tracer uptake studies. After 2 h of 18F-LMI1195 preloading into both cell lines, effects of stimulants for storage
vesicle turnover (high concentration KCl (100 mM) or reserpine treatment) were measured at 10, 20, and 30 min.
131I-meta-iodobenzylguanidine (131I-MIBG) served as a reference. Both high concentration KCl and reserpine
enhanced 18F-LMI1195 washout from PC12 cells, while tracer retention remained stable in the SK-N-SH cells. After
30 min of treatment, 18F-LMI1195 releasing index (percentage of tracer released from cells) from vesicle-rich PC12
cells achieved significant differences compared to cells without treatment condition. In contrast, such effect could
not be observed using vesicle-poor SK-N-SH cell lines. Similar tracer kinetics after KCl or reserpine treatment were
also observed using 131I-MIBG. In case of KCl exposure, Ca2+-free buffer with the calcium chelator,
ethylenediaminetetracetic acid (EDTA), could suppress the tracer washout from PC12 cells. This finding is consistent
with the tracer release being mediated by Ca2+ influx resulting from membrane depolarization.
Conclusions: Analogous to 131I-MIBG, the current in vitro tracer uptake study confirmed that 18F-LMI1195 is also
stored in vesicles in PC12 cells and released along with vesicle turnover. Understanding the basic kinetics of 18F-
LMI1195 at a subcellular level is important for the design of clinical imaging protocols and imaging interpretation.
Keywords: Heart failure, Sympathetic nervous system, Storage vesicle turnover, Positron emission tomography,
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Background
The single-photon emission computed tomography
(SPECT) tracer 123I-meta-iodobenzylguanidine (MIBG) tar-
geting norepinephrine transporter (NET) is currently the
most widely used clinical tracer for sympathetic nervous
imaging with well-established protocols and mature
guidelines based on the results achieved from several clin-
ical trials [1, 2]. However, positron emission tomography
(PET) tracers show beneficial properties compared with
SPECT tracers due to the development of imaging technol-
ogy over the last couple of decades. PET provides superior
sensitivity and improved temporal and spatial resolution
along with the possibilities of regional cardiac imaging and
kinetic studies for quantification [3]. Among the PET
tracers that are currently available for NET imaging, a new
class of 18F-labeled agents has drawn attention because of
their longer half-life of fluorine-18 (110 min) over carbon-
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11 (20 min). Thereby, these 18F-labeled tracers provide a
unique opportunity to further enhance the development
and application of PET imaging in terms of reduction of
the financial burden of hospitals, flexible novel tracer de-
sign, and labeling procedure with improved stabilities [4].
Currently, a couple of 18F-labeled tracers targeting the
NET are available: N-[3-bromo-4-(3-18F-fluoropropoxy]-
benzyl]-guanidine (18F-LMI1195) is designed for assess-
ment of sympathetic innervation of the heart and has
successfully passed through phase I clinical trial, which
confirmed its tolerance in human subjects along with favor-
able biodistribution for cardiac imaging [5]. [18F]4-fluoro-3-
hydroxyphenethylguanidine ([18F]4F-MHPG) and its iso-
mer [18F]3-fluoro-4-hydroxyphenethylguanidine ([18F]3F-
PHPG) have also been developed in order to counteract the
perfusion dependence compared to previous NET tracers
[6]. The first-in-human studies of both tracers showed clear
and long-term cardiac retention [7].
All the abovementioned tracers share a similar structure
(benzyl/phenethyl guanidine) as MIBG and therefore rep-
resent comparable properties. Among them, 18F-LMI1195
has so far caught most of the attentions from researchers
due to its easy and high-yield labeling procedure that is
convenient and eligible for commercial preparation and
application [8, 9]. Similar to MIBG, 18F-LMI1195 is resist-
ant to metabolism by monoamine oxidase [5, 10]. In a
head-to-head comparison of 18F-LMI1195 with 123I-MIBG
in isolated perfused rabbit hearts, tracer washout after
vesicle turnover was accelerated by electrical field stimula-
tion. Additionally, our group has also demonstrated that
the retention of 18F-LMI1195 is resistant to desipramine
chase (desipramine added after tracer delivery), which em-
phasizes its potential of mimicking the physiological nor-
epinephrine turnover [11].
Nonetheless, although our former investigation on iso-
lated rabbit rat heart has proved the accumulation of 18F-
LMI1195 in nerve terminals, it was not sufficient enough
to come to the conclusion that it was taken up into the
vesicles. In a previous study, by using potassium chloride
(KCl) and reserpine stimulation, the difference between
extravesicular retention and granular storage of MIBG
was clearly demonstrated in PC12 (vesicle-poorvesicle-
rich) and SK-N-SH (vesicle-richvesicle-poor) cell lines
[12]. Therefore, in order to gain further insights and clar-
ify the kinetics of 18F-LMI1195 at a subcellular level, we
aimed to compare it with its SPECT counterpart 131I-
MIBG in both cell lines, as mentioned above, with regard
to KCl or reserpine-induced tracer depletion mechanisms.
High concentration of KCl has been applied as a simulant
of electrical field stimulation that enhances cardiac
LMI1195 washout significantly in the isolated rabbit heart
[11]. Reserpine can also deplete catecholamines (in this
case, 18F-LMI1195 that presumably mimics neurotrans-
mitter) from storage vesicles [13]. By accomplishing this
study, it might be possible and prove necessary to investi-
gate the likely drug-tracer competition and to compare
the different tracer uptake behavior and mechanism de-
tails. The conclusions achieved from the results will serve
as a useful guidance for future clinical assessment.
Methods
Radiopharmaceuticals
18F-LMI1195 was synthesized and purified as described in
the literature [8]. The radiochemical purity of the final
product was greater than 95% with a specific radioactivity
more than 10 GBq/μmol. 131I-MIBG was purchased from
GE Healthcare (Freiburg im Breisgau, Germany) and used
within 2 h after calibration time. 131I-MIBG was chosen in-
stead of 123I-MIBG due to its relative longer half-life, which
is convenient for research purposes and financial reasons.
Cell culture
Both PC12 cells (adrenal gland pheochromocytoma from
rat) and SK-N-SH cells (human neural cells from Cauca-
sian neuroblastoma) were purchased from Sigma-Aldrich
(Sigma-Aldrich Chemie GmbH, Munich, Germany) and
were cultivated at 37 °C and 5% CO2. PC12 cells were
grown in a Roswell Park Memorial Institute medium with
2 mM glutamine, 5% fetal bovine serum (FBS), and 10%
horse serum. SK-N-SH cells were grown in MEM medium
with 2 mM glutamine and 10% FBS. The cells were first
grown in 75-cm2 flasks with type IV collagen coating, in
which the cells would be adherent. One day prior to re-
lease assay, they were transferred to 12-well plates with
1 mL volume per well and 2 × 105/mL density.
Release assay
High concentration KCl-induced tracer release
Firstly, cells were incubated with high concentration KCl
(100 mM) for 10, 20, and 30 min. The total protein con-
centrations after incubation were compared with control
groups using only HEPES buffered saline (HBS) buffer (cf.
Additional file 1) to insure the cell viability. No statistical
difference could be concluded from these two groups.
Therefore, this incubation condition was used for the fol-
lowing high concentration KCl induction study.
The culture medium was removed and the cells were
washed with the medium. Cells were first incubated with
radiotracers in a solution containing both 18F-LMI1195
(300 kBq) and 131I-MIBG (37 kBq) at 37 °C for 120 min.
After incubation, the cells were washed twice with
warmed HBS buffer. One milliliter of HBS buffer was
added again followed with 5 min incubation before re-
moval. Then, cells were treated with HBS (with or without
Ca2+) or 100 mM high KCl buffer (with or without Ca2+)
for 10, 20, and 30 min. After the treatment, the buffer was
collected as the extracellular fraction. Cells were washed
twice with ice-cold phosphate buffered saline (PBS) and
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solubilized in 0.1 N NaOH. Radioactivity in each sample
was measured using a gamma counter using differential
energy windows (± 20%) for 18F and 131I (FH412; Frieseke
& Höpfner, Erlangen, Germany).
Reserpine-induced tracer release
Tracer loadings were performed in analogy to the above-
mentioned KCl study. Cells were incubated with radio-
tracers in a solution containing both 18F-LMI1195
(300 kBq) and 131I-MIBG (37 kBq) at 37 °C for 120 min.
After the incubation period, cells were washed twice with
warmed medium, followed by 5 min incubation with
medium. Afterwards, cells were treated with a reserpine
solution at final concentrations of 50 nM for PC12 cells
and 5 μM for SK-N-SH cells for 10, 20, or 30 min, respect-
ively, because it is known that PC12 cells are sensitive to
reserpine-induced depletion, whereas a much higher con-
centration of reserpine is applied to SK-N-SH cells be-
cause of its dramatically lower storage capacity [13]. The
incubation buffer was collected followed by double wash-
ing with ice-cold PBS. The cells were then solubilized in
0.1 N NaOH, and the cell lysate was collected. Radioactiv-
ity of each sample was measured using a gamma counter.
Nonspecific uptake was measured in the presence of
10 μM of the selective NET inhibitor desipramine, and
specific uptake was calculated by subtracting nonspecific
radioactivity from total counts.
Retention index calculation
To quantify tracer release from cells, a retention index
was calculated as
Retention index %ð Þ ¼ 100 1−release counts=total countsð Þ;
in which release counts are defined as counts bound to
extracellular buffer after release stimulation. Total counts
are the counts bound to cell lysate after the tracer uptake
period (including the washing process). To exclude non-
specific binding or uptake (which does not contribute to
release after vesicular turnover), non-specific uptake was
determined in the presence of 10 μM desipramine and
subtracted from total uptake.
Statistics
All experimental data are presented as mean ± SD, with
individual numbers measured in triplicate in experi-
ments performed on 2–3 separate days. Statistical com-
parison of uptake/release ratios between two groups was
performed by Student’s t test, where p values of less than
0.05 were considered statistically significant. Data were
analyzed by analysis of variance (ANOVA) when mul-
tiple groups were compared. Statistical analysis was per-
formed on GraphPad Prism (GraphPad Software, Inc.,
La Jolla, USA).
Results
High concentration KCl-induced tracer depletion
Treatment of PC12 cells with high concentration KCl buf-
fer induced robust tracer depletion of both 18F-LMI1195
and 131I-MIBG in a time-dependent manner, leading to
88 ± 4% of 18F-LMI1195 and 70 ± 2% of 131I-MIBG total
uptake released from cells (p < 0.001, vs. untreated con-
trols, Fig. 1a). In contrast, KCl did not produce an obvious
release of either 18F-LMI1195 or 131I-MIBG in SK-N-SH
cells and demonstrated similar retention indices as con-
trols (Fig. 1b).
Tracer depletion in PC12 cells 30 min after treatment
with high concentration KCl could be overturned by
using Ca2+-free buffer containing ethylenediaminetetra-
acetic acid (EDTA) (Fig. 2). The release index (as per-
centage of tracer released from cells after certain
treatment) of 18F-LMI1195 decreased from 71 ± 4%
(100 mM KCl) to 16 ± 7% (100 mM KCl + EDTA). By in-
vestigating 131I-MIBG, the same tendency with a de-
crease from 61 ± 2% (100 mM KCl) to 15 ± 4% (100 mM
KCl + EDTA) was observed (p < 0.005, respectively).
The release of 18F-LMI1195 from PC12 cells by ex-
posure to reserpine was time-dependent and reached
significant differences after 30 min of treatment. This
result is in accordance with our findings for 131I-
MIBG (Fig. 3a). LMI1195 uptake reached a significant
difference (p < 0.001) after 30 min of reserpine expos-
ure with only 68 ± 3% left (vs. 80 ± 2% in controls). A
similar pattern of tracer kinetics was confirmed using
131I-MIBG after reserpine exposure with retention of
65 ± 7% for the reserpine-treated group versus 85 ± 3%
for the control group (p < 0.001). Applying the same
protocol on SK-N-SH cells (vesicle-poor), 88 ± 2% re-
tention of 18F-LMI1195 and 87 ± 2% of 131I-MIBG in
the cells were recorded. However, no statistical differ-
ence was reached either for 18F-LMI1195 or for 131I-
MIBG (Fig. 3b). Co-exposing the preloaded PC12 cells
to both reserpine and the NET blocker desipramine,
the tracer release showed a similar pattern to using
reserpine alone with significant differences after
30 min of treatment (Fig. 3a vs. Fig. 4).
In summary, high concentration KCl and reserpine
could enhance 18F-LMI119 washout from storage
vesicle-rich PC12 cells. This washout as quantified as
tracer releasing index could reach a significant differ-
ence after 30 min of treatment. In contrast, such ef-
fect could not be observed while using vesicle-poor
SK-N-SH cells. As a golden reference, similar kinetics
after KCl or reserpine treatment were also achieved
using 131I-MIBG in the same cell lines. Furthermore,
high concentration KCl exposure-induced tracer re-
lease was Ca2+ dependent as confirmed by suppress-
ing the effect using calcium chelator EDTA and Ca2
+-free buffer.
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Discussion
Several tracers sharing similarities in their benzylguani-
dine structure were designed to compensate for the dis-
advantages of the clinically used SPECT tracer MIBG.
They all represent similarities to MIBG in order to
achieve comparable in vitro intracellular retention and
in vivo distribution properties [14]. Among them, 18F-
LMI1195 is so far the best examined 18F-labeled PET
tracer and has successfully proceeded with a clinical
phase I trial [5]. In addition to the current literatures [5,
8, 9, 15], our research group has also performed a num-
ber of investigations with 18F-LMI1195 using animal
models and ex vivo systems [11, 16, 17]. A further un-
derstanding of the properties of 18F-LMI1195 and its
performance at a subcellular and molecular level is still
of importance for its clinical application.
Therefore, we investigated the storage mechanism and
depletion kinetics of LMI1195 on both rat pheochromocy-
toma PC12 and human neuroblastoma SK-N-SH cells,
using 131I-MIBG as a comparator. The former cell line is
rich of storage vesicles that could retain either the physio-
logical neurotransmitter norepinephrine or radioactive
tracers with analogous structures, whereas the SK-N-SH
cells are poor of such secretory vesicles, and therefore, the
Fig. 1 Time course of tracer retention index after the stimulation with high concentration KCl buffer. Both 18F-LMI1195 and 131I-MIBG were
induced to be released from (vesicle-rich) PC12 cells after high concentration KCl buffer treatment (a n = 3 at each time point of both groups),
whereas no such effect could be observed in (vesicle-poor) SK-N-SH cells (b n = 3 at each time point of both groups). ***p < 0.001 vs. control
group at the same time point; all data points presented as mean ± SD
Fig. 2 Comparison of both tracers in PC12 cells treated with 100 mM KCl in the presence (+) or absence (−) of EDTA. Y-axis represents the
difference of release index, i.e., counts over control after 30 min of treatment with high concentration KCl buffer. Both 18F-LMI1195 (n = 3 of each
testing group) and 131I-MIBG (n = 3 of each testing group) were released from PC12 cells after treatment with high concentration KCl in the
absence of EDTA, whereas the effect was mitigated in the presence of EDTA. **p < 0.005 vs. EDTA (+) group at the same condition; all data points
presented as mean ± SD
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taken-up tracers can only be stored in cytoplasm or mito-
chondria [18]. All cells were first preloaded with both
tracers to reach equilibrium and thereafter were treated
with either high concentration KCl buffer or reserpine in
order to trigger the depletion of preloaded radiotracers.
As shown in Fig. 1, depolarization of PC12 cells caused
by stimulation of high concentration KCl buffer evoked ap-
parent tracer release, with approximately 60–70% depletion
of additional 18F-LMI1195 or 131I-MIBG from the cells. By
applying high concentration KCl to neuronal cells, Blaus-
tein has proposed that neurotransmitter release from the
nerve terminal is caused by Ca2+ influx via voltage-gated
calcium channels [19]. Therefore, when using either Ca2
+-free KCl buffer with Ca2+ chelator ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) or cal-
cium channel blocker nifedipine, Araujo et al. further veri-
fied the suppression of norepinephrine release [20]. Similar
conclusions were also drawn by Mandela et al. yielding that
norepinephrine depletion is dependent on extracellular Ca2
+ and could be fully suppressed by EDTA [21]. Thus, as ex-
pected, the outcome of exposing cells to Ca2+-free high KCl
buffer containing EDTA lead to comparable findings in our
study with a diminished release effect (Fig. 2).
This result attained from high KCl induction is con-
sistent with the conclusion achieved from our research
group using isolated rabbit hearts, in which the electrical
Fig. 3 Time course of tracer retention index after the stimulation with reserpine. Both tracers are induced to be released from PC12 cells after
reserpine treatment (a n = 6 at each time point of both groups), whereas such effect could not be observed in SK-N-SH cells (b n = 6 at each time
point of both groups). ***p < 0.001 vs. control group at the same time point; all data points presented as mean ± SD
Fig. 4 Co-exposing preloaded PC12 cells to reserpine and desipramine. The co-treatment also induced tracer release in the same mode as using
reserpine alone. The release indices of either 18F-LMI1195 (left, n = 6 at each time point of both groups) or 131I-MIBG (right, n = 6 at each time
point of both groups) reached significant differences compared to controls after 30 min. ***p < 0.001 vs. control group at the same time point; all
data points presented as mean ± SD
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provocation evoked enhanced tracer release [11]. Elec-
trical field stimulation is known to induce norepineph-
rine overflow by releasing storage vesicles [22]. Since we
could measure the radioactivity in the whole heart, in-
cluding neuronal cells and myocytes, it was suggested
that 18F-LMI1195 was taken up by the cells and stored
within the vesicles [11]. In addition to our previous find-
ings, we further confirmed this distinct uptake, storage,
and release characteristics by using an in vitro assay.
As a human neuroblastoma cell line, SK-N-SH also ex-
presses NET on the plasma membrane [23] and they are
able to transport either 131I-MIBG or 18F-LMI1195 into
cells. However, due to the shortage of storage vesicles,
no apparent release of stored tracers could be observed
after the application of high KCl buffer compared to
controls (Fig. 1b). The response of high KCl-leading
tracer release compared with the control group is of ut-
most importance: Since no statistical difference could be
observed between both groups, a robust conclusion can
be derived from the setup of our experiment.
Reserpine is known for its potential to release norepineph-
rine from synaptic nerve cells by triggering the exocytosis of
storage vesicles [21]. In this study, reserpine induced signifi-
cant tracer release after 30 min of its application to vesicle-
rich PC12 cells (Fig. 3), whereas such an effect was not
observed in SK-N-SH cells, which is in accordance with the
conclusion drawn by Smets et al. from a reserpine-induced
MIBG depletion study [24]. Due to the deficiency of storage
vesicles in SK-N-SH cells, no clear tracer overflow, either
with 18F-LMI1195 or 131I-MIBG, could be observed. The ef-
flux of tracers from SK-N-SH cells may be only due to slow
passive diffusion. The current study of using either high
concentration KCl or reserpine is the opposite way as the re-
sults achieved from rabbit heart [16], in which pretreatment
of desipramine was followed by tracer injection (Fig. 5).
Firstly, this in vivo study provided the first proof of success-
fully prohibiting the uptake of tracer into storage vesicles by
using desipramine. Secondly, the in vitro cell study
demonstrated the clear depletion mechanism of an already
taken-up tracer in the storage vesicles. By comparing the
two methods (high concentration KCl and reserpine), it was
revealed that the application of these exogenous radioactive
sympathetic nerve tracers apparently mimics the physio-
logical neurotransmitter norepinephrine turnover quite well,
including transporter-mediated uptake as well as modes of
storage and exocytosis (Fig. 6). Integrating our previous ani-
mal study (Fig. 5) and ex vivo results [11, 16, 17] with the
present in vitro findings, the intracellular behavior of 18F-
LMI1195 is analogous to its SPECT counterpart MIBG and
the neurotransmitter norepinephrine.
Similar to high KCl-induced exocytosis, reserpine-
mediated 18F-LMI1195 release is also Ca2+ dependent.
Mandela et al. have investigated and reported how reser-
pine influences NET in a non-competitive manner by Ca2
+ dependency and how it interferes with the interaction
between NET and norepinephrine storage vesicles. Strik-
ingly, it was revealed that reserpine induces a non-
competitive inhibition of norepinephrine uptake in PC12
cells [13]. This effect requires the presence of vesicular
monoamine transporter (VMAT) and storage/secretory
vesicles, which explains the finding for exposure to reser-
pine alone and reserpine/desipramine-induced tracer
release—a demonstration of analogous uptake and efflux
mechanisms associated with the benzylguanidine structure
common to both tracers (Fig. 4). By contrast, as demon-
strated previously, cardiac retention of 11C-hydroxyephe-
drine (11C-HED) is mediated through a continuous
cyclical mode of release (diffusion out) and reuptake via
NET from the nerve terminal [11, 16]. 11C-HED showed
enhanced washout from both in vivo and isolated perfused
rabbit heart after desipramine chase. On the other hand,
18F-LMI1195 and MIBG are not sensitive to a NET inhibi-
tor chase protocol in an in vivo setting, which was
imitated in the present in vitro study by adding desipra-
mine while incubating with reserpine (Fig. 4). Therefore,
on a subcellular level, a stable vesicle-storing mechanism
Fig. 5 Transverse image of 18F-LMI1195 uptake in rabbit heart, showing control (left) and with DMI pretreatment (right). Averaged scan
10–30 min after tracer injection. With permission of [16]
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mimicking physiological norepinephrine turnover was
corroborated.
It should be mentioned that in addition to the applica-
tion of these NET tracers in cardiac diseases, there are
many potential applications in tumor diagnosis [25]. 123I-
MIBG imaging had been used in the evaluation of neuro-
blastoma for years [26]. 18F-LMI1195 would also be avail-
able because of their structural and property similarities in
NET imaging: A previous study of high and specific accu-
mulation of LMI1195 in pheochromocytomas has already
made the first attempt in proving this potential [15].
Conclusions
Our study demonstrated the subcellular and molecular
uptake and release mechanism of the novel sympathetic
nerve PET tracer 18F-LMI1195. These findings are analo-
gous to findings for the structurally related and widely
used SPECT predecessor MIBG. Both high concentration
KCl and reserpine induce the depletion of 18F-LMI1195.
The proposed mechanism of vesicle storage and release is
consistent with the conclusions suggested from previous
studies using both ex vivo isolated perfused and in vivo
rabbit hearts. To sum up, we herein demonstrated that
18F-LMI1195 is a promising tracer for visualizing the car-
diac innervation by mimicking the physiologic neurotrans-
mitter norepinephrine. It can provide similar properties as
MIBG in a clinical setting along with the advantages of
18F-labeling and PET imaging technology.
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